Study | Age at vaccination (in years) | Vaccine efficacy against HZ | Waning or duration of protection | Vaccination coveragea | Vaccination costs per dose (2010 EUR, German price level) |
---|---|---|---|---|---|
Annemans et al. [65] | 50+ | 37.6-63.9Â %, age-dependent | No waningb | 20Â % | EUR 141.39c |
Bilcke et al. [38] | 60-85 | Age-dependent (values are reported graphically only) | Consideration of waning depends on the choice of scenario | 30Â % | EUR 106.95d |
Bilcke et al. [30] | 50 or 60 | 77 %e | Duration of protection of 7.5Â years or lifelong protection | 30Â % or 70Â % | EUR 103.38d |
Bresse et al. [66] | 65+ | 18-64Â %, age-dependent | 4.15Â % per year and vaccine efficacy was set to zero after 10Â years | 20Â % | EUR 117f |
Brisson et al. [67] | 50-80 | 26-75Â %, age-dependent | No waningb | Not specified | EUR 108.60 |
de Boer et al. [40] | 60-75 | 41.2-69.4Â %, age-dependent | 8.3Â % per year (= duration of protection of 12Â years) | Not specified | EUR 89.10d |
Edmunds et al. [68] | 65 | 30-70Â % | Duration of protection of 2.5Â years to life long | 60Â % | EUR 122.13d,g |
Hornberger et al. [28] | 69 | Modelled by applying age-specific incidence of HZ in vaccine and placebo-treated arm of the clinical study, age-dependent | Duration of protection of 30Â years | Not specified | EUR 43.85-438.46d,h |
Moore et al. [69] | 50+ | 37.6-63.9Â %, age-dependent | No waningb | 40Â % | EUR 143.28d |
Najafzadeh et al. [26] | 60+ | Modelled by applying age-specific incidence of HZ in vaccine and placebo-treated arm of the clinical study, age-dependent | 4.5Â % per year | Not specified | EUR 101.83 |
Pellissier et al. [70] | 60+ | 27.1-69.8Â %, age-dependent | No waningb | Not specified | EUR 147.32d |
Rothberg et al. [42] | 60-80 | Age-dependent | Waning considered but not quantified | Not specified | EUR 134.74d |
Szucs et al. [71] | 70-79 | 37.60-63.9Â %, age-dependent | No waningb | 20Â % | EUR 143.09d |
Ultsch et al. [39] | 50-80 | 13.22-69.8Â %, age-dependent | 8.3Â % per year following 10Â years of stable vaccine efficacy | 20Â % | EUR 147.48d |
van Hoek et al. [72] | 60-75 | 31-95Â % (based on 15 different take and waning scenarios), age-dependent | Duration of protection of 3.6-100 years (based on 15 different take and waning scenarios) | 73.5Â % | EUR 88.36d |
van Hoek et al. [33] | 75 | Data from van Hoek et al. [72] | Data from van Hoek et al. [72] | 70Â % | EUR 86.37d |
van Lier et al. [41] | 60-80 | Data from van Hoek et al. [72] | Duration of protection of 7.5Â years | 75Â % | EUR 81.54d |